What Are Mesothelioma Blood Tests?
Blood tests for mesothelioma identify specific substances produced by the cancer cells. These molecules are called biomarkers. They can be detected in a blood sample when a person has mesothelioma.
Examples of Mesothelioma Blood-Test Biomarkers
- MESOMARK assay
- N-ERC/Mesothelin Test
- Fibulin-3 Test
- Megakaryocyte potentiation factor
Currently, these mesothelioma blood tests are being used in combination with imaging scans such as X-rays and CT scans to improve the accuracy and speed of cancer diagnosis.
All of these steps and tests can lead to the collection of a tissue biopsy and a pathology work up. Pathologists can closely examine cancer cells collected during surgery or biopsy.
Using sophisticated lab tests, these specialist doctors can not only differentiate mesothelioma from other tumor types, but also determine the type of mesothelioma and its genetic makeup.
Immunohistochemical markers are one example of the complex laboratory studies your pathologist may use to provide the most accurate diagnosis. This, in turn, allows your oncologists to develop the best treatment plan for your unique cancer type.
How Do Mesothelioma Blood Tests Work?
Mesothelioma blood tests work because these biomarkers tend to be produced in very small amounts or not at all by healthy cells. This means the substances normally aren’t present in a blood sample from a person without mesothelioma.
For some tumors, the proteins are unique to that specific cancer. Identifying them will indicate a person has that particular cancer.
Mesothelioma-specific biomarkers are being used as blood tests for the asbestos-related disease. They rely on the presence of proteins in the blood that only a mesothelioma tumor is likely to produce.
Other Uses for Mesothelioma Biomarkers
Mesothelioma biomarkers are being investigated for other important purposes, too. Along with helping diagnose the disease, these substances can be directly targeted to treat mesothelioma.
For example, mesothelin is a biomarker produced by mesothelioma. Ongoing clinical trials are removing patients’ immune cells, modifying them in the lab to specifically target the mesothelin on mesothelioma cells and infusing them back into the body.
Promising results from this approach were presented at the 2019 American Society of Clinical Oncology meeting. Eleven of 14 patients in the trial experienced a complete response, partial response or stable disease after an average follow up of nearly three years.
An assay is a test performed in a lab. The MESOMARK assay measures the quantity of SMRP (serum-measured soluble mesothelin-related peptide) in a patient’s blood sample. Abnormally high SMRP levels may indicate the presence of mesothelioma.
Some types of mesothelioma, such as sarcomatoid tumors, do not release high levels of SMRP. For this reason, the FDA recommends doctors combine the MESOMARK assay with other tests to ensure an accurate mesothelioma diagnosis.
Some insurance companies do not cover this particular blood test. However, if you have a history of asbestos exposure and therefore are at high risk for developing mesothelioma, ask your doctor if the MESOMARK assay is something you should consider.
Elevated SMRP levels identified by the MESOMARK test can help with initial mesothelioma diagnosis and sometimes are checked to monitor the cancer’s response to treatment. Declining levels may indicate the treatment is working.
Other malignant diseases, such as pancreatic cancer, ovarian cancer and primary lung cancers, may produce elevated SMRP levels. This is one drawback of the MESOMARK assay: It is not specific just to mesothelioma.
The MESOMARK Assay Procedure
The MESOMARK assay is completed in two steps. First, your doctor will collect a blood sample and send it to a laboratory for analysis.
Next, laboratory technicians add antibodies to the blood sample. These antibodies bind to SMRP and fragments of this protein.
Computer software analyzes the blood sample and provides a measurement of the levels of SMRP-bound antibodies. SMRP levels at or above a certain reference point may suggest the presence of mesothelioma or another malignant pleural disease.
The MESOMARK blood test may someday serve as a screening tool for patients at high risk for mesothelioma who don’t yet have the disease.
Currently, it is only used in diagnosing suspected cases of mesothelioma, although a 2019 meta-analysis identified mesothelin blood levels as significantly lower in all control groups compared with people who have malignant pleural mesothelioma.
This suggests mesothelin may be a good candidate for a screening biomarker in people at high risk of developing mesothelioma.
The N-ERC/Mesothelin test detects a specific form of mesothelin known as N-ERC/mesothelin.
The test is similar to MESOMARK, but it uses a specially designed enzyme to find a particular version of the mesothelin molecule. This increases the test’s accuracy.
The N-ERC/mesothelin test is 95% effective at detecting mesothelioma. However, it is only 76% effective at ruling mesothelioma out because mesothelin is produced by a few other types of cancer, too.
Even though it is more accurate than MESOMARK, the N-ERC/Mesothelin blood test cannot serve as a single test to diagnose mesothelioma.
Fibulin-3 is a protein produced by mesothelioma cells. It can be detected in pleural fluid and blood. Mesothelioma specialist Dr. Harvey Pass helped develop and validate the fibulin-3 test for mesothelioma diagnosis.
In 2012, he co-authored a study demonstrating fibulin-3 is 96.7% effective at detecting mesothelioma and 95.5% effective for ruling it out in people without the disease.
Other studies have found the test less effective for detecting mesothelioma, depending on when and how it is used. For example, when used on blood samples previously collected from mesothelioma patients, it was not as accurate.
A 2019 meta-analysis found significantly higher fibulin-3 blood levels in people with mesothelioma compared with all non-mesothelioma control groups, making it a potentially effective blood test biomarker in people at high risk of developing mesothelioma.
Free Mesothelioma Guide
Free information, books, wristbands and more for patients and caregivers.Get Your Free Guide
Other Biomarker-Based Blood Tests
Other mesothelioma biomarker tests determine levels of osteopontin and megakaryocyte potentiation factor (MPF) in blood samples.
Researchers have demonstrated mesothelioma patients have higher concentrations of these biomarkers compared with healthy individuals or patients with other cancers.
Osteopontin and MPF blood tests are not dependable or accurate enough to make a definitive mesothelioma diagnosis, but they can play a significant role in monitoring the disease once a diagnosis is confirmed with X-rays, CT scans and tissue biopsies.
Human Osteopontin ELISA Kit from R–D Systems
Osteopontin levels are elevated in mesothelioma patients — even when compared to patients with benign asbestos-related conditions such as asbestosis and pleural thickening.
This means the human osteopontin ELISA kit is a reliable biomarker test for differentiating between healthy asbestos-exposed individuals and those who have developed mesothelioma.
Other diseases can elevate osteopontin levels too, including cancers of the lung, colon and breast and tuberculosis, and osteopontin cannot differentiate malignant mesothelioma and these conditions.
It can be useful for screening asbestos-exposed populations, monitoring treatment and predicting prognosis for mesothelioma patients.
Human Megakaryocyte Potentiation Factor (MPF) ELISA Kit
Blood tests can identify the presence of a biomarker called megakaryocyte potentiation factor (MPF). Doctors do not fully understand the biological function of MPF, but they know it is released into the bloodstream of mesothelioma patients in extremely high quantities.
In one small study, laboratory technicians identified MPF in blood samples from 91% of late-stage patients. They did not detect MPF in the blood of healthy donors, although ovarian cancer and pancreatic cancer also can lead to elevated MPF blood levels.
While the MPF biomarker test alone cannot provide an accurate diagnosis, levels may decrease after effective mesothelioma treatments such as successful surgical debulking.
This indicates that MPF blood testing can help monitor a patient’s response to surgery.
Other Blood Test Biomarkers
When asbestos fibers enter the body, damage begins to occur. Doctors can monitor the byproducts of asbestos-related cell to potentially track the progression of asbestos-related disease.
8OHdG is a biomarker indicating cell damage due to oxidation. This biomarker may be present in blood samples during the early stages of cancer development. Elevated 8OHdG levels can occur in people occupationally exposed to asbestos and have been linked to asbestosis.
This biomarker is produced by many cancers, not just mesothelioma. Additionally, exposure to cigarette smoke and heavy metals can create 8OHdG.
However, higher 8OHdG levels correlate with more severe asbestosis. One study found the combination of 8OHdG and the biomarkers VEGFbeta and SMRPs is effective for identifying people with varying degrees of asbestos exposure.
While ER-β is not used to diagnose mesothelioma, it may be useful for prognosis and treatment decisions. A 2014 study found higher levels of activated ER-β in pleural mesothelioma cells improved response to cisplatin chemotherapy.
Epidermal Growth Factor Receptor (EGFR)
Like ER-β, EGFR is activated by asbestos exposure and may play a role in the development of mesothelioma. Because EGFR is produced by a variety of cancers, it cannot be used to diagnose mesothelioma. However, it may be useful for monitoring treatment response.
A 2017 study published in the journal BMC Cancer detailed the possible use of the blood biomarker calretinin to improve mesothelioma diagnosis.
The team of Australian and German researchers developed a test to detect calretinin in blood samples and found it performed similarly to mesothelin. Calretinin appears most likely to improve diagnosis epithelioid and biphasic disease, but not sarcomatoid cell mesothelioma.
17 Cited Article Sources
The sources on all content featured in The Mesothelioma Center at Asbestos.com include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.
Jiménez-Ramírez, C. et al. (2019, July 2). Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma. doi: 10.1007/s00408-019-00244-1
Adusumilli, P.S. et al. (2019, June). Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent.
Retrieved from: https://abstracts.asco.org/239/AbstView_239_269679.html
Ledda, C. et al. (2019, June 25). Fibulin-3 as biomarker of malignant mesothelioma. doi: 10.2217/bmm-2018-0285
Gillezeau, C. et al. (2019, June 5). Biomarkers for malignant pleural mesothelioma: a meta-analysis. doi: 10.1093/carcin/bgz103
Clinical Trials.gov. (2019, May 17). Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin.
Retrieved from: https://clinicaltrials.gov/ct2/show/NCT02414269
Ledda, C. et al. (2018, June 15). Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on. doi: 10.3390/cancers10060203
Johnen, G. et al. (2017, May 30). Calretinin as a blood-based biomarker for mesothelioma.
Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450182/
Pington, G. et al. (2014, October 2). Agonist activation of estrogen receptor beta (ER?) sensitized malignant pleural mesothelioma cells to cisplatin cytotoxicity. doi: 10.1186/1476-4598-13-227
Sato, T. et al. (2014, October). Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma. doi: 10.1002/cam4.297
Creaney, J. et al. (2014, July). Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. doi:10.1136/thoraxjnl-2014-205205
Agha, M.A. et al. (2014, January). Role of fibulin-3 in the diagnosis of malignant mesothelioma. doi: 10.1016/j.ejcdt.2013.10.004
Mezzapelle, R. et al. (2013, April 30). Mutation analysis of the EGFR gene and downstream signaling pathway in histologic samples of malignant pleural mesothelioma. doi:10.1038/bjc.2013.130
Pass, H.I. et al. (2012, October 11). Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. doi: 10.1056/NEJMoa1115050
Imashimizu, K. et al. (2011, May-June). Feasibility of large-scale screening using N-ERC/mesothelin levels in the blood for the early diagnosis of malignant mesothelioma.
Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440716/
Hassan, R. et al. (2010, June). Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.
Retrieved from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864325/
Tomasetti, M. and Santarelli, L. (2010, April 14). Biomarkers for early detection of malignant mesothelioma: Diagnostic and therapeutic application. doi:10.3390/cancers2020523
- Amati, M. et al. (2008, January). Profiling tumor-associated markers for early detection of malignant mesothelioma: An epidemiologic study. doi: 10.1158/1055-9965.EPI-07-0607
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?
Share this article
Last Modified July 29, 2019